Key result
FMDV virus-like particles produced in a CHO cell-based transient gene expression system induced protective antibody titers in swine up to 60 days post-vaccination.
Why the study?
Current foot-and-mouth disease vaccines require high biosafety standards and are costly, while alternative platforms fail to meet industrial scalability, cost-efficiency, or multiserotype flexibility.
CHO cell-based transient gene expression is a feasible, scalable platform for producing immunogenic FMDV VLPs for recombinant vaccines.
TGE system may enable scalable FMDV vaccines; leaves open industrial validation for cost-efficiency and multiserotype flexibility.
BACKGROUND/OBJECTIVES: Foot-and-mouth disease virus (FMDV) poses a continuous threat to livestock health and agricultural economies. Current vaccines require high biosafety standards and are costly to produce. While novel vaccine technologies have been explored, most fail to meet industrial scalability, cost-efficiency, or multiserotype flexibility required for effective FMD control. This study aimed to evaluate the feasibility of using a high-cell density transient gene expression (TGE) system in CHO cells for the production of FMDV virus-like particles (VLPs) as a recombinant vaccine platform. METHODS: VLP expression was optimized by adjusting cDNA and polyethyleneimine (PEI) concentrations. Expression yields were compared at 24 and 48 h post-transfection to determine optimal harvest timing. We further tested the system's capacity to express different serotypes and chimeric constructs, incorporating VP1 sequences from various FMDV strains. Immunogenicity was evaluated in swine using VLPs from the A2001 Argentina strain as a model. RESULTS: titer 1.43) and liquid-phase blocking ELISA (LPBE, titer 2.20) at 28 days post-vaccination (dpv). Titers remained above protective thresholds up to 60 dpv with a single dose. A booster at 28 dpv further elevated titers to levels comparable to those induced by the inactivated vaccine. CONCLUSIONS: Our results demonstrate the feasibility of using CHO cell-based TGE for producing immunogenic FMDV VLPs. This platform shows promise for scalable, cost-effective, and biosafe development of recombinant FMD vaccines.
No takes yet. Share an insight, caveat, or question.
Mignaqui et al. (2025) studied Foot-and-mouth disease. FMDV virus-like particles (A2001 Argentina strain) vs. Inactivated vaccine was evaluated on Immunogenicity (antibody titers). FMDV virus-like particles produced in a CHO cell-based transient gene expression system induced protective antibody titers in swine up to 60 days post-vaccination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: